Influence of BCG vaccine strain on the immune response and protection against tuberculosis

FEMS Microbiology Reviews

Volumn 32, Issue 5, 2008, Pages 821-841

  Ritz, Nicole ^a,b   Hanekom, Willem A ^c   Robins Browne, Roy ^a,b   Britton, Warwick J ^d   Curtis, Nigel ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bacille Calmette Gu rin; BCG; Immunity; Strain; Tuberculosis

Indexed keywords

BCG VACCINE;

BACTERIAL VIRULENCE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFICACY; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL;

BCG VACCINE; CHILD; CHILD, PRESCHOOL; HUMANS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

ANIMALIA;

EID: 49649094290     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1111/j.1574-6976.2008.00118.x     Document Type: Review

References (117)

1. Aguirre-Blanco AM, Lukey PT, Cliff JM Dockrell HM (2007) Strain-dependent variation in Mycobacterium bovis BCG-induced human T-cell activation and gamma interferon production in vitro. Infect Immun 75: 3197 3201.
2. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER Harrison LH (2004) Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 291: 2086 2091.
3. Behar SM, Dascher CC, Grusby MJ, Wang CR Brenner MB (1999) Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J Exp Med 189: 1973 1980.
4. Behr MA (2002) BCG - different strains, different vaccines? Lancet Infect Dis 2: 86 92.
5. Behr MA Small PM (1997) Has BCG attenuated to impotence? Nature 389: 133 134.
6. Behr MA Small PM (1999) A historical and molecular phylogeny of BCG strains. Vaccine 17: 915 922.
7. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S Small PM (1999) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284:1520 1523.
8. Bottiger M, de Verdier C, Lind A, Beskow R, Linden G Granath B (1983) A comparative study of Danish (Statens Seruminstitut), Glaxo and Behringwerke vaccines - revaccination of schoolchildren. J Biol Stand 11:1 12.
9. Brewer TF (2000) Preventing tuberculosis with Bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 31 (Suppl 3): S64 S67.
10. Brosch R, Gordon SV, Garnier T et al 2007) Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 104: 5596 5601.
11. Bunch-Christensen K, Ladefoged A Guld J (1968) The virulence of some strains of BCG for golden hamsters. Bull World Health Organ 39: 821 828.
12. Bunch-Christensen K, Ladefoged A Guld J (1970) The virulence of some strains of BCG for golden hamsters. Further studies. Bull World Health Organ 43: 65 70.
13. Buraczewska M, Chodkowska S Paklerska-Pobratyn H (1969) Comparison of the Brazilian, Russian and French BCG substrains based on the "safety test". Pol Med J 8: 1136 1142.
14. Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR Flynn JL (1999) Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 162: 5407 5416.
15. Castillo-Rodal AI, Castanon-Arreola M, Hernandez-Pando R, Calva JJ, Sada-Diaz E Lopez-Vidal Y (2006) Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. Infect Immun 74: 1718 1724.
16. Castro-Rodriguez JA, Mallol J, Andrade R, Munoz M Azzini I (2007) Comparison of tuberculin skin test response after three modalities of neonatal BCG vaccination. Trans R Soc Trop Med Hyg 101: 493 496.
17. + T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis. Infect Immun 69: 2666 2674.
18. Chan SL, Allen G Pio A (1966) Comparison of the efficacy of two strains of BCG vaccine for prevention of tuberculosis among newborn children in Hong Kong. Bull Int Union Tuberc 61: 36 37.
19. Charlet D, Mostowy S, Alexander D, Sit L, Wiker HG Behr MA (2005) Reduced expression of antigenic proteins MPB70 and MPB83 in Mycobacterium bovis BCG strains due to a start codon mutation in sigK. Mol Microbiol 56: 1302 1313.
20. Chege GK, Williamson AL, Passmore JS, Bourn W, Ryffel B Shephard EG (2005) The immune response of the Chacma baboon to Bacille Calmette-Guerin: development of a primate model for BCG-based vaccine research. Vaccine 23: 5783 5791.
21. Choi HS, Rai PR, Chu HW, Cool C Chan ED (2002) Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis. Am J Respir Crit Care Med 166: 178 186.
22. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV Mosteller F (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271: 698 702.
23. Collins FM (1985) Protection to mice afforded by BCG vaccines against an aerogenic challenge by three mycobacteria of decreasing virulence. Tubercle 66: 267 276.
24. Comstock GW (1988) Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 138: 479 480.
25. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG Orme IM (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178: 2243 2247.
26. Cooper AM, Magram J, Ferrante J Orme IM (1997) Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 186:39 45.
27. Corbel MJ, Fruth U, Griffiths E Knezevic I (2004) Report on a WHO consultation on the characterisation of BCG strains, Imperial College, London, 15-16 December 2003. Vaccine 22:2675 2680.
28. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC Dye C (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163:1009 1021.
29. Cruz A, Khader SA, Torrado E et al 2006) Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol 177:1416 1420.
30. Dannenberg AM Jr. Collins FM (2001) Progressive pulmonary tuberculosis is not due to increasing numbers of viable bacilli in rabbits, mice and guinea pigs, but is due to a continuous host response to mycobacterial products. Tuberculosis (Edinburgh) 81:229 242.
31. Davids V, Hanekom WA, Mansoor N et al 2006) The effect of Bacille Calmette-Guerin vaccine strain and route of administration on induced immune responses in vaccinated infants. J Infect Dis 193:531 536.
32. Dorman SE, Picard C, Lammas D et al 2004) Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 364:2113 2121.
33. Elias D, Akuffo H Britton S (2005) PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans Royal Soc Trop Med Hyg 99:363 368.
34. Fernando SL Britton WJ (2006) Genetic susceptibility to mycobacterial disease in humans. Immunol Cell Biol 84:125 137.
35. Fine PEM, Sterne JAC, Ponnighaus JM Rees RJW (1994) Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 344:1245 1249.
36. Fletcher HA (2007) Correlates of immune protection from tuberculosis. Curr Mol Med 7:319 325.
37. Flynn JL, Goldstein MM, Triebold KJ, Koller B Bloom BR (1992) Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 89:12013 12017.
38. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA Bloom BR (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178:2249 2254.
39. Flynn JL, Goldstein MM, Chan J et al 1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561 572.
40. Foulds KE, Wu CY Seder RA (2006) Th1 memory: implications for vaccine development. Immunol Rev 211:58 66.
41. Galbraith NS Hall CJ (1974) Comparative trials of British BCG vaccine double strength, and Danish BCG vaccine, with standard strength British BCG vaccine. Tubercle 55:283 289.
42. Gheorghiu M Lagrange PH (1983) Viability, heat stability and immunogenicity of four BCG vaccines prepared from four different BCG strains. Ann Immunol (Paris) 134C:125 147.
43. Gorak-Stolinska P, Weir RE, Floyd S et al 2006) Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine. Vaccine 24:5726 5733.
44. Griffin JF, Mackintosh CG Buchan GS (1995) Animal models of protective immunity in tuberculosis to evaluate candidate vaccines. Trends Microbiol 3:418 424.
45. + T lymphocytes in control of Mycobacterium tuberculosis infection. Microbes Infect 7:776 788.
46. Guerin N, Teulieres L, Noba A, Schlumberger M, Bregere P Chauvin P (1999) Comparison of the safety and immunogenicity of the lyophilized Merieux seed and the World Health Organization working reference BCG vaccines in school-aged children in Senegal. Vaccine 17:105 109.
47. Gupta UD Katoch VM (2005) Animal models of tuberculosis. Tuberculosis (Edinburgh) 85:277 293.
48. Hanekom WA (2005) The immune response to BCG vaccination of newborns. Ann NY Acad Sci 1062:69 78.
49. Hank JA, Chan JK, Edwards ML, Muller D Smith DW (1981) Influence of the virulence of Mycobacterium tuberculosis on protection induced by Bacille Calmette-Guerin in guinea pigs. J Infect Dis 143:734 738.
50. Hengster P, Schnapka J, Fille M Menardi G (1992) Occurrence of suppurative lymphadenitis after a change of BCG vaccine. Arch Dis Child 67:952 955.
51. Ho MM, Corbel MJ, Knezevic I Roumiantzeff M (2005) Report on a WHO consultation on the characterisation of BCG vaccines, WHO, Geneva, Switzerland, 8-9 Dec 2004. Vaccine 23:5700 5704.
52. Hoft DF, Kemp EB, Marinaro M et al 1999) A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal Bacille Calmette-Guerin vaccination. J Lab Clin Med 134:244 252.
53. Hoft DF, Worku S, Kampmann B et al 2002) Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis 186:1448 1457.
54. Horwitz O Bunch-Christensen K (1972) Correlation between tuberculin sensitivity after 2 months and 5 years among BCG vaccinated subjects. Bull World Health Organ 47:49 58.
55. Hussey GD, Watkins MLV, Goddard EA et al 2002) Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies. Immunology 105:314 324.
56. Junior LP Gontijo Filho PP (1979) Comparative immunogenicity of BCG substrains for mice. Rev Bras Pesqui Med Biol 12:311 316.
57. Junqueira-Kipnis AP, Kipnis A, Jamieson A et al 2003) NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J Immunol 171:6039 6045.
58. Kamath AT, Hanke T, Briscoe H Britton WJ (1999) Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis. Immunology 96:511 516.
59. Kamath AT, Fruth U, Brennan MJ et al 2005) New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23:3753 3761.
60. Kaufmann SH (2005) Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol 26:660 667.
61. Kaufmann SH Flesch IE (1988) The role of T cell-macrophage interactions in tuberculosis. Springer Semin Immunopathol 10:337 358.
62. Knezevic I Corbel MJ (2006) WHO discussion on the improvement of the quality control of BCG vaccines. Vaccine 24:3874 3877.
63. Kroger L, Korppi M, Brander E et al 1995) Osteitis caused by bacille Calmette-Guerin vaccination: a retrospective analysis of 222 cases. J Infect Dis 172:574 576.
64. Ladefoged A, Bunch-Christensen K Guld J (1970) The protective effect in bank voles of some strains of BCG. Bull World Health Organ 43:71 90.
65. Ladefoged A, Bunchchristensen K Guld J (1976) Tuberculin sensitivity in Guinea-Pigs after vaccination with varying doses of BCG of 12 different strains. Bull World Health Organ 53:435 443.
66. Lagranderie MR, Balazuc AM, Deriaud E, Leclerc CD Gheorghiu M (1996) Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun 64:1 9.
67. Langermans JA, Andersen P, van Soolingen D et al 2001) Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc Natl Acad Sci USA 98:11497 11502.
68. Lindblad EB, Elhay MJ, Silva R, Appelberg R Andersen P (1997) Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 65:623 629.
69. Martin C (2006) Tuberculosis vaccines: past, present and future. Curr Opin Pulmon Med 12:186 191.
70. Milstien JB Gibson JJ (1990) Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 68:93 108.
71. Mostowy S, Tsolaki AG, Small PM Behr MA (2003) The in vitro evolution of BCG vaccines. Vaccine 21:4270 4274.
72. + T cell response. J Immunol 177:5647 5651.
73. Narayanan PR (2006) Influence of sex, age and nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized control trial in South India. Indian J Med Res 123:119 124.
74. Nathan C (2006) Role of iNOS in human host defense. Science 312:1874 1875.
75. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R Levin M (1996) A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 335:1941 1949.
76. Nyboe J Bunch-Christensen K (1966) Assay in man of different BCG products. Bull World Health Organ 35:645 650.
77. O'Garra A Britton WJ (2008) Cytokines in tuberculosis. Handbook of Tuberculosis: Immunology and Cell Biology (Kaufmann SHE Britton WJ, eds), pp. 185 225. Wiley-VCH Hoboken, NJ.
78. Oettinger T, Jorgensen M, Ladefoged A, Haslov K Andersen P (1999) Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis 79:243 250.
79. Olsen AW, Hansen PR, Holm A Andersen P (2000) Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 30:1724 1732.
80. Ordway DJ, Costa L, Martins M et al 2004) Increased interleukin-4 production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis. J Infect Dis 190:756 766.
81. Ota MO, Goetghebuer T, Vekemans J, Okoko BJ, Newport MJ, McAdam KP Marchant A (2006) Dissociation between tuberculin skin test and in vitro IFN-gamma responses following neonatal BCG vaccination. J Trop Pediatr 52:136 140.
82. Pinto R, Saunders BM, Camacho LR, Britton WJ, Gicquel B Triccas JA (2004) Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guerin vaccine. J Infect Dis 189:105 112.
83. Pruchova J Sir Z (1972) Comparative assay of immunization potencies of the Czechoslovak, Danish and Japanese vaccines as a preliminary step to the seed lot system in the production of BCG vaccine in Czechoslovakia. Prog Immunobiol Stand 5:442 446.
84. + regulatory T cells during early mycobacterial infection increases cytokine production but does not affect pathogen load. Immunol Cell Biol 84:467 474.
85. Rodgers A, Whitmore KM Walker KB (2006) Potential correlates of BCG induced protection against tuberculosis detected in a mouse aerosol model using gene expression profiling. Tuberculosis (Edinburgh) 86:255 262.
86. Rook GAW, Hernandez-Pando R, Dheda K Teng Seah G (2004) IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 25:483 488.
87. Roth A, Sodemann M, Jensen H et al 2005) Vaccination technique, PPD reaction and BCG scarring in a cohort of children born in Guinea-Bissau 2000-2002. Vaccine 23:3991 3998.
88. Roth A, Sodemann M, Jensen H et al 2006) Tuberculin reaction, BCG scar, and lower female mortality. Epidemiology 17:562 568.
89. Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H Britton WJ (2005) Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 174:4852 4859.
90. Schroder K, Hertzog PJ, Ravasi T Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163 189.
91. Selwyn PA, Hartel D, Lewis VA et al 1989) A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320:545 550.
92. Shann F (2004) Heterologous immunity and the nonspecific effects of vaccines: a major medical advance? Pediatr Infect Dis J 23:555 558.
93. Skeiky YA Sadoff JC (2006) Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4:469 476.
94. Skinner MA, Ramsay AJ, Buchan GS et al 2003) A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis. Immunology 108:548 555.
95. Smerak P, Pruchova J Sir Z (1982) Comparison of bcg strains for delayed hypersensitivity induction tested in vivo in guinea pigs and in vitro. J Hyg Epidemiol Microbiol Immunol 26:435 444.
96. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B Godfrey-Faussett P (2001) HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358:1687 1693.
97. Soysal A, Millington KA, Bakir M et al 2005) Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366:1443 1451.
98. Stefanova T, Chouchkova M, Hinds J et al 2003) Genetic composition of Mycobacterium bovis BCG substrain Sofia. J Clin Microbiol 41:5349.
99. Sterne JAC, Fine PEM, Ponnighaus JM, Sibanda F, Munthali M Glynn JR (1996) Does bacille Calmette-Guerin scar size have implications for protection against tuberculosis or leprosy? Tubercle Lung Dis 77:117 123.
100. Suciliene E, Ronne T, Plesner AM, Semenaite B, Slapkauskaite D, Larsen SO Haslov K (1999) Infant BCG vaccination study in Lithuania. Int J Tuberc Lung Dis 3:956 961.
101. Swaminathan S, Ramachandran R, Baskaran G et al 2000) Risk of development of tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis 4:839 844.
102. Triccas JA, Sun L, Palendira U Britton WJ (2002) Comparative affects of plasmid-encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis. Immunol Cell Biol 80:346 350.
103. Trunz BB, Fine P Dye C (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367:1173 1180.
104. Tuberculosis Research Centre (ICMR) (1999) Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res 110:56 69.
105. Vallishayee RS, Shashidhara AN, Bunch-Christensen K Guld J (1974) Tuberculin sensitivity and skin lesions in children after vaccination with 11 different BCG strains. Bull World Health Organ 51:489 494.
106. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM Andersen P (2000) Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 30:3689 3698.
107. Vijayalakshmi V, Murthy KJ, Kumar S Kiran AL (1995) Comparison of the immune responses in children vaccinated with three strains of BCG vaccine. Indian Pediatr 32:979 982.
108. Viney ME, Riley EM Buchanan KL (2005) Optimal immune responses: immunocompetence revisited. Trends Ecol Evol 20:665 669.
109. Walker V, Selby G Wacogne I (2006) Does neonatal BCG vaccination protect against tuberculous meningitis? Arch Dis Child 91:789 791.
110. Wang GZ, Balasubramanian V Smith DW (1988) The protective and allergenic potency of four BCG substrains in use in China determined in two animal models. Tubercle 69:283 291.
111. Wangoo A, Sparer T, Brown IN et al 2001) Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 166:3432 3439.
112. Williams A, Hatch GJ, Clark SO et al 2005) Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinburgh) 85:29 38.
113. Winau F, Hegasy G, Kaufmann SH Schaible UE (2005) No life without death-apoptosis as prerequisite for T cell activation. Apoptosis 10:707 715.
114. Winau F, Weber S, Sad S et al 2006) Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24:105 117.
115. Wozniak TM, Ryan AA, Triccas JA Britton WJ (2006) Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect Immun 74:557 565.
116. Wu B, Huang C, Garcia L et al 2007) Unique Gene expression profiles in infants vaccinated with different strains of Mycobacterium bovis Bacille Calmette-Guerin. Infect Immun 75:3658 3664.
117. Yakuwa E (1953) Comparative studies on the Japanese and French strain of BCG. Sci Rep Res Inst Tohoku Univ [Med] 5:35 46.